India's drug price regulator raised ceiling rates for two key platinum-based cancer drugs by 50% after a surge in raw material costs triggered widespread shortages, according to a government notification seen by Reuters.
The National Pharmaceutical Pricing Authority invoked special provisions to raise rates for the drugs after receiving federal government approval citing public interest, according to the notification dated June 11.
